Literature DB >> 10889925

Human oral squamous cell carcinoma cell lines promote angiogenesis via expression of vascular endothelial growth factor and upregulation of KDR/flk-1 expression in endothelial cells.

Y Michi1, I Morita, T Amagasa, S Murota.   

Abstract

Angiogenesis is an important phenomenon for the growth and metastasis of solid tumors. The present study examined the characterization of angiogenic factors produced by human oral squamous cell carcinoma (oral SCC) cell lines established from lymph node metastatic tumors and primary tumor in different patients. The conditioned medium of HSC3 with the strongest metastatic ability among the examined lines enhanced a tube-forming activity of bovine carotid artery endothelial (BAE) cells in collagen gel cultures. The treatment of HSC3 with anti-vascular endothelial growth factor (VEGF) antibody or anti-basic fibroblast growth factor (bFGF) antibody, either alone or in combination, attenuated the activity of urokinase-type plasminogen activator (uPA) in the endothelial cells stimulated by the conditioned medium of HSC3. In contrast, neither anti-interleukin-8 (IL-8) antibody nor anti-hepatocyte growth factor (HGF beta) antibody affected uPA activity in the endothelial cells. Among these HSC cell lines, HSC3 secreted VEGF with the highest (1.92 +/- 0.24 ng/10(6) cells/24 h) level and bFGF. The level of bFGF secreted by HSC3 was lower than that secreted by BAE cells. Other oral SCC cell lines secreted lower levels of VEGF and undetectable levels of bFGF. By reverse transcriptase-polymerase chain reaction analysis of mRNA the production of VEGF121, VEGF145, VEGF165, VEGF189, and VEGF206 in these cell lines was able to be detected. Moreover, the conditioned medium of HSC3 enhanced the tyrosine phosphorylation and expression of kinase insert domain-containing receptor (KDR/flk-1) in the endothelial cells. These results suggest that oral SCC promotes angiogenesis via expression of VEGF and upregulation of their receptor KDR/flk-1 expression in endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10889925     DOI: 10.1016/s1368-8375(99)00059-7

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  6 in total

1.  VEGFR1 and VEGFR2 in lip carcinogenesis and its association with microvessel density.

Authors:  Carla Ariotti; Vivian Petersen Wagner; Gabriela Salvadori; Vinicius Coelho Carrard; Marco Antônio Trevizani Martins; Joao Julio da Cunha Filho; Luise Meurer; Manoela Domingues Martins
Journal:  Tumour Biol       Date:  2015-04-21

2.  Inostamycin suppresses vascular endothelial growth factor-stimulated growth and migration of human umbilical vein endothelial cells.

Authors:  Yuh Baba; Yasumasa Kato; Izumi Mochimatsu; Yoji Nagashima; Miki Kurihara; Toshiro Kawano; Takahide Taguchi; Ryu-Ichiro Hata; Mamoru Tsukuda
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

3.  Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent.

Authors:  J T Lucas; B P Salimath; M G Slomiany; S A Rosenzweig
Journal:  Oncogene       Date:  2010-05-24       Impact factor: 9.867

4.  Released lipids regulate transient receptor potential channel (TRP)-dependent oral cancer pain.

Authors:  Shivani Ruparel; Michelle Bendele; Ashley Wallace; Dustin Green
Journal:  Mol Pain       Date:  2015-05-26       Impact factor: 3.395

5.  EXPRESS: BDNF Signaling Contributes to Oral Cancer Pain in a Preclinical Orthotopic Rodent Model.

Authors:  Leah Chodroff; Michele Bendele; Vanessa Valenzuela; Michael Henry; Shivani Ruparel
Journal:  Mol Pain       Date:  2016-09-02       Impact factor: 3.395

6.  Water extract of Clinacanthus nutans leaves exhibits in vitro, ex vivo and in vivo anti-angiogenic activities in endothelial cell via suppression of cell proliferation.

Authors:  Chin Theng Ng; Lai Yen Fong; Jun Jie Tan; Nor Fadilah Rajab; Faridah Abas; Khozirah Shaari; Kok Meng Chan; Fariza Juliana; Yoke Keong Yong
Journal:  BMC Complement Altern Med       Date:  2018-07-06       Impact factor: 3.659

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.